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Inherited, complete deficiency of human HOIL-, a component of the linear ubiquitination 
chain assembly complex (LUBAC), underlies autoinflammation, infections, and amylo-
pectinosis. We report the clinical description and molecular analysis of a novel inherited 
disorder of the human LUBAC complex. A patient with multiorgan autoinflammation, 
combined immunodeficiency, subclinical amylopectinosis, and systemic lymphangiectasia, is 
homozygous for a mutation in HOIP, the gene encoding the catalytic component of LUBAC. 
The missense allele (L72P, in the PUB domain) is at least severely hypomorphic, as it impairs 
HOIP expression and destabilizes the whole LUBAC complex. Linear ubiquitination and  
NF-B activation are impaired in the patient’s fibroblasts stimulated by IL- or TNF. In 
contrast, the patient’s monocytes respond to IL- more vigorously than control mono-
cytes. However, the activation and differentiation of the patient’s B cells are impaired in 
response to CD40 engagement. These cellular and clinical phenotypes largely overlap those 
of HOIL--deficient patients. Clinical differences between HOIL-- and HOIP-mutated 
patients may result from differences between the mutations, the loci, or other factors. Our 
findings show that human HOIP is essential for the assembly and function of LUBAC and 
for various processes governing inflammation and immunity in both hematopoietic and 
nonhematopoietic cells.
© 2015 Boisson et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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autoinflammation, combined immunodeficiency, infections, 
subclinical amylopectinosis, and systemic lymphangiectasia due 
to a homozygous missense mutation of HOIP (RNF31), en-
coding the catalytic component of LUBAC.
RESULTS
Identification of a homozygous HOIP missense mutation
We investigated a patient born to consanguineous parents 
of Kuwaiti descent, who presented with multiorgan auto-
inflammation, systemic lymphangiectasia, weakness at lower 
extremities, subclinical amylopectinosis, and a combined 
immunodeficiency manifesting as chronic diarrhea and re-
current viral and bacterial infections, associated with lympho-
penia, antibody deficiency and an impaired distribution and 
function of T lymphocytes (see case report and Table S1). 
Periodic Acid-Schiff staining of sternocleidomastoid muscular 
biopsy showed patches of granular or subsarcolemmal PAS-
positive material that was resistant to treatment with diastase, 
consistent with amylopectinosis, but there were no clinical, 
electrographic, or echographic signs of skeletal myopathy 
or cardiomyopathy (Fig. 1 A). We set out to decipher the 
underlying genetic defect by genome-wide linkage (GWL) 
and whole-exome sequencing (WES; Bolze et al., 2010; 
Byun et al., 2010; Itan et al., 2013; Casanova et al., 2014; 
Conley and Casanova, 2014). We did not find rare variants 
in known autoinflammation and immunodeficiency genes 
(Al-Herz et al., 2014; Conley and Casanova, 2014) and in 
known lymphangiectasia-causing genes (CCBE1, FOXC2, 
VEGFR3, SOX18, and GJC2; Alitalo, 2011). We hypothesized 
that this novel, rare condition would follow an autosomal re-
cessive inheritance. We therefore filtered out all heterozy-
gous and common variant. We found 38 homozygous rare 
variants in as many genes (minor allele frequency ≤1%; Table S2). 
GWL by homozygosity mapping with a model of complete 
penetrance further reduced the list of variations to 15 candi-
date genes (Table S2). These variants included a homozygous 
T-to-C substitution at position 215 (c.215T>C) in exon 2 of 
HOIP (also known as RNF31), which was identified in the 
patient and confirmed by Sanger sequencing (Fig. 1, B and C). 
This missense substitution results in the replacement of a 
leucine residue by a proline residue at the start of the PUB 
(PNGase [peptide N-glycosidase]/ubiquitin-associated) do-
main of HOIP (Fig. 1 D). Both parents and the healthy 
sibling of the patient were heterozygous for the mutation 
(Fig. 1, B and C). The HOIP L72P variant was not found in 
public databases (NCBI, UCSC, 1000 genomes, or ExAC, 
reaching a total of up to 60,706 individuals) or in our 
own WES database (2,212 individuals). Possibly relevant to 
the patient’s clinical phenotype, HOIP encodes HOIL-1– 
interacting protein, the catalytic components of LUBAC, an 
E3 ligase complex (Fig. 1 D) responsible for adding head-to-
tail linear polyubiquitin chains to substrate proteins, includ-
ing NEMO (Kirisako et al., 2006; Iwai and Tokunaga, 2009; 
Tokunaga et al., 2009; Smit et al., 2012; Sasaki et al., 2013), 
RIP1 (Gerlach et al., 2011), and ASC (Boisson and Casanova, 
2014; Rodgers et al., 2014). No rare mutations were found 
The description and analysis of inborn errors of human NF-
B–mediated immunity began in 2001 with the discovery of 
X-linked recessive anhidrotic ectodermal dysplasia with immuno-
deficiency (EDA-ID) caused by hypomorphic mutations in 
NEMO (encoding NF-B essential modulator; Döffinger et al., 
2001), followed by the description of autosomal dominant 
EDA-ID caused by hypermorphic mutations of the NFKBIA 
gene (encoding IB) in 2003 (Courtois et al., 2003). These 
defects lead to a broad range of infections, caused by impaired 
signaling by various membrane receptors involved in innate 
and adaptive immunity, including TLR/IL1R and TNFRs 
(Puel et al., 2004; Casanova et al., 2011; Picard et al., 2011; 
Boisson et al., 2015). Gain-of-function mutations of IB 
are also associated with a profound T cell deficiency (Courtois 
et al., 2003). Other global defects of NF-B activation 
were later discovered, including autosomal recessive IKK 
deficiency (Pannicke et al., 2013; Mousallem et al., 2014; 
Nielsen et al., 2014) in the canonical pathway and autosomal-
dominant NFKB2 deficiency (Lee et al., 2014; Lindsley et al., 
2014) and autosomal recessive NIK deficiency (Willmann 
et al., 2014) in the alternative pathway.
There are many more inborn errors of specific pathways 
involving NF-B caused by mutations in receptors or their 
ligands, such as CD40 (Ferrari et al., 2001) and CD40L (Allen 
et al., 1993; DiSanto et al., 1993) deficiency. Mutations may 
also affect cytosolic components, as illustrated by defects of 
TLR/IL-1-dependent NF-B–mediated immunity in patients 
with autosomal recessive IRAK-4 and MyD88 deficiencies 
(Picard et al., 2003; von Bernuth et al., 2008; Picard et al., 
2010; Casanova et al., 2011; Alsina et al., 2014). Patients with 
these two deficiencies are prone to life-threatening pyogenic 
bacterial diseases (Picard et al., 2010). In these inborn errors 
of immunity, signs of inflammation during infection are 
either absent or delayed (Picard et al., 2011). Collectively, 
these experiments of nature highlight the diversity of cells 
and receptors that engage NF-B activation. They provide 
some explanation for some of the clinical phenotypes seen in 
patients with inborn errors of core NF-B components. How-
ever, most of these receptors can normally also engage other 
signaling pathways, somewhat blurring some of the latter 
clinical phenotypes.
Surprisingly, bi-allelic mutations of HOIL1, encoding one 
of the three proteins of the linear ubiquitination chain assem-
bly complex (LUBAC), a component of the NF-B cascade 
involved in IKK complex activation (Iwai and Tokunaga, 
2009; Tokunaga et al., 2009; Fujita et al., 2014; Popovic et al., 
2014), were recently shown to underlie autoinflammation, 
immunodeficiency, and amylopectinosis (Boisson et al., 2012). 
The assembly of LUBAC was impaired but its function was 
not tested. The fibroblasts of HOIL-1–deficient patients dis-
play impaired responses to TLR agonists, IL-1, and TNF, 
and their B cells display an impaired response to CD40L. In 
contrast, monocytes from these patients respond more strongly 
than control monocytes to IL-1 (Boisson et al., 2012). Sim-
ilar findings were recently documented in a mouse model 
(MacDuff et al., 2015). We report here a patient with diffuse 
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amplified and sequenced the full-length cDNA, but no splic-
ing defect was detected (unpublished data). Examination of 
HOIP protein levels by immunoblotting revealed that no 
mutant protein was detected (Fig. 2 B) in patient’s fibroblasts 
and EBV-B–transformed cells. We failed to restore the ex-
pression of the HOIP L72P protein in the patient’s fibroblasts 
by inhibiting proteasome-, lysosome-, or autophagy-mediated 
protein clearance with MG-132, leupeptin, or 3-Methyladenine, 
respectively (unpublished data). This suggests that translation 
of HOIP L72P mRNAs, or stability of nascent L72P pro-
teins, or both, is impaired. LUBAC contains three subunits: 
HOIP, HOIL-1, and the SHANK-associated RH domain-
interacting protein (SHARPIN; Kirisako et al., 2006; Iwai 
and Tokunaga, 2009; Gerlach et al., 2011; Ikeda et al., 2011; 
Tokunaga et al., 2011; Stieglitz et al., 2013). We assessed the 
abundance of the other two components of LUBAC in con-
trol and patient’s fibroblasts and EBV-B cells. SHARPIN and 
HOIL-1 protein levels were lower in the cells from the pa-
tient than in control cells (Fig. 2 B). We investigated the 
composition of LUBAC in the patient’s cells further by per-
forming immunoprecipitation experiments with antibodies 
against HOIP and SHARPIN, and monitoring the levels 
of the other two components of the complex. Only trace 
amounts of HOIP were detected in the patient’s fibroblasts 
in HOIL-1 and SHARPIN. The HOIP missense mutation 
affects the conserved PUB domain of HOIP (Fig. 1 E), which 
has recently been shown to be important for the interaction 
of HOIP with OTULIN and CYLD, two deubiquitinases 
(Elliott et al., 2014; Fujita et al., 2014; Schaeffer et al., 2014). 
SIFT and Polyphen algorithms predicted a deleterious impact 
of this mutation on the function of the N-terminal domain 
(Table S2). Finally, the combined annotation dependent de-
pletion score, a method for integrating many diverse annota-
tions into a single measure (Kircher et al., 2014), predicted 
a deleterious impact of the L72P missense mutation (score 
of 22.2). Moreover, the HOIP gene does not harbor overtly 
deleterious mutations (nonsense, indels, essential splice muta-
tions) at MAF higher than 1/100,000 in public and in-house 
databases, further suggesting that homozygosity for the L72P 
HOIP mutation could be disease-causing in the patient.
Impaired HOIP and LUBAC expression
We first assessed the impact of the mutation by analyzing 
HOIP mRNA levels by reverse transcription-quantitative 
PCR in SV40-transformed fibroblasts from patients and con-
trols. The patient’s cells contained 50% less HOIP mRNA 
than control cells (Fig. 2 A). This mutation is located close to 
the acceptor splicing site of exon 2 (+6). We therefore also 
Figure . A patient with a homozygous germline 
HOIP mutation. (A) Amylopectin accumulation in bowel 
tissue from HOIP-deficient patient. Patient sternocleido-
mastoid muscular biopsy was stained with hematoxylin 
and eosin (H&E), or with periodic acid-Schiff stain (PAS) 
after diastase pretreatment (PASD). A patchy accumula-
tion of PAS+diastase-resistant material in a scattered 
muscle fibers is shown in patient’ biopsy. Bar, 50 µm. 
(B) Pedigree of the kindred, showing segregation of the 
L72P missense mutation. (C) HOIP DNA sequence elec-
tropherograms, for controls, the patient and her family. 
(D) Schematic diagram of the LUBAC complex. The do-
mains identified are depicted as boxes: PNGase/UBA or 
UBX (PUB), ubiquitin-like (UBL), novel zinc-finger (NZF), 
really interesting new gene (RING) domain, in-between 
RING (IBR) domain, zinc finger (ZF). The red star indicates 
the position of the L72P mutation. Double arrows indi-
cate the domain involved in the interaction between 
subunits. (E) Amino acid sequences alignment of the PUB 
domain of HOIP orthologues. The L72 residue is high-
lighted in red. The hashtags indicate the amino acids 
conserved in all proteins containing a PUB domain.
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that, in response to cytokine stimulation, the IKK complex is 
rapidly and transiently relocalized and activated into supra-
molecular complexes (Tarantino et al., 2014), which act as a 
marker of the early steps of NF-B activation. As already re-
ported for HOIL-1–deficient fibroblasts (Tarantino et al., 2014), 
we found that the IL-1 –induced formation of NEMO-
containing structures was almost entirely abolished in HOIP 
L72P-expressing fibroblasts (Fig. 3 C), whereas NEMO- 
containing complexes formed normally in the same cells treated 
with TNF. Finally, we examined the formation of linear poly-
ubiquitin chains in control and HOIP-deficient fibroblasts 
treated with cytokines. Using an antibody that specifically 
recognizes linear polyubiquitin linkages (Matsumoto et al., 
2012), we detected linear polyubiquitin aggregates in TNF- 
and IL-1–treated control cells, but almost none in the pa-
tient’s cells (Fig. 3 D). Overall, these data indicate that linear 
ubiquitination and NF-B activation by IL-1 and TNF is 
impaired in fibroblasts from the patient with the HOIP muta-
tion. Moreover, the IL-1 response is more severely affected 
than the TNF response, as previously shown for HOIL-1 de-
ficiency (Boisson et al., 2012). Overall, these findings show 
that the fibroblastic phenotype of HOIP-mutated patients is 
as severe as that of HOIL-1–deficient patients, suggesting that 
the HOIP allele is at least strongly hypomorphic and perhaps 
completely loss-of-function.
and EBV-B cells (Fig. 2 C). However, HOIL-1 and SHARPIN 
were still found to be associated as previously shown (Ikeda 
et al., 2011). Interestingly, although HOIL-1 was detected as 
a doublet in SDS-PAGE gels for control cells, only the lower 
MW product was associated with SHARPIN in the patient’s 
cells (Fig. 2 B). Thus, the L72P mutation destabilizes the HOIP 
protein and, consequently, the overall LUBAC complex. 
These findings suggest that the L72P allele of HOIP is almost 
loss-of-expression.
Impaired NF-B activation in the patient’s fibroblasts
LUBAC regulates activation of the canonical NF-B path-
way, which plays a key role in inflammatory and immune 
responses (Tokunaga et al., 2009; Gerlach et al., 2011). We 
therefore assessed the functionality of the canonical NF-B 
pathway in patient-derived SV40-transformed fibroblasts. 
Cells from a HOIL-1–deficient patient were also included in 
this study (Boisson et al., 2012). The HOIP-mutated patient’s 
fibroblasts displayed impaired IKK phosphorylation and de-
layed IB degradation in response to TNF or IL-1, as ob-
served for HOIL-1–deficient fibroblasts (Fig. 3 A). These cells 
also displayed a marked impairment of IL-6 production after 
stimulation with TNF and IL-1, as shown by ELISA (Fig. 3 B). 
Again, these findings were similar to those for HOIL-1– 
deficient cells. Using confocal microscopy, we recently showed 
Figure 2. HOIP deficiency. (A) Relative HOIP mRNA 
levels in SV40-immortalized fibroblasts from controls, 
the HOIP-deficient patient (Patient), and HOIL-1– 
deficient patients (two independent experiments).  
(B) Expression of LUBAC subunits in control, HOIP-, and 
HOIL-1–deficient fibroblasts (left) and control and HOIP-
deficient EBV-B cells (right) by immunoblotting total cell 
extracts with the indicated antibodies (two independent 
experiments). (C) Immunoblot of immunoprecipitated 
extracts from control, HOIP-, and HOIL-1–deficient fibro-
blasts (left) and control and HOIP-deficient EBV-B cells 
(right) with antibodies directed against HOIP (IP-HOIP) or 
SHARPIN (IP-SHARPIN) and detected with HOIL-1, HOIP, 
or SHARPIN antibodies (two independent experiments).
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HOIP-deficient B cells do not respond to CD40L stimulation
The HOIP-deficient patient has hypogammaglobulinemia 
and nonprotective antibody responses to Streptococcus pneu-
moniae and Haemophilus influenzae. LUBAC has been shown 
to be important for the activation of B cells via the CD40 
pathway in mice (Hostager et al., 2010, 2011; Sasaki et al., 
2013) and in humans (Boisson et al., 2012). We therefore in-
vestigated the possible impairment of CD40 signaling in pri-
mary B cells from the HOIP-deficient patient. The stimulation 
of control B cells with CD40L plus IL-21 or CD40L plus IL-4 
led to an increase in CD80 expression, as previously reported 
(Kennedy et al., 1994). In contrast, a marked impairment 
of CD80 up-regulation was observed with B cells from the 
patient (Fig. 5 A). Nevertheless, they were able to respond to 
BCR stimulation (anti-IgM plus CpG ± BAFF), suggesting 
that BCR activation is only partially dependent on LUBAC 
(Fig. 5 A). Stimulation of PBMCs with CD40L plus IL-21 is 
also known to induce differentiation of primary naive B cells 
to plasmablasts (Recher et al., 2011). We therefore explored 
plasmablast generation after stimulation of control and patient 
PBMCs with CD40L plus IL-21. After 7 d, the proportion of 
CD19+ B cells that were also CD27hi CD38hi (identifying 
plasmablasts) was markedly lower for the patient than for the 
control (Fig. 5 B). We further tested the activation of the 
canonical NF-B pathway upon stimulation by CD40L in 
EBV-B cells from the patient. We found reduced IB degrada-
tion and impaired phosphorylation of IKKs in HOIP-mutated 
Restoration of LUBAC stability and NF-B  
activation by the wild-type HOIP allele
The L72P missense mutation is responsible for the desta-
bilization of HOIP and, consequently, of the other two 
LUBAC subunits and the whole LUBAC complex, impair-
ing NF-B responses. In an attempt to rescue the biochem-
ical and cellular phenotype, we reintroduced WT HOIP 
(N-terminally tagged), by retroviral transduction, into con-
trol, HOIP-, and HOIL-1–deficient fibroblasts. This ge-
netic complementation led to the reappearance of the higher 
molecular weight HOIL-1 protein species on immunoblots 
(Fig. 4 A). It also led to the stabilization of SHARPIN not 
only in patient cells, but also in HOIL-1/ cells. More-
over, it led to an increase in the phosphorylation of IKK ki-
nases and faster IB degradation, similar to that reported 
for control cells stimulated with TNF or IL-1 (Fig. 4 B). 
Finally, cells from the patient complemented with the WT 
HOIP allele produced similar amounts of IL-6 to control 
cells in response to stimulation with TNF or IL-1 (Fig. 4 C). 
In contrast, the introduction of WT HOIP into HOIL-1–
deficient cells did not restore the production of IL-6 in re-
sponse to stimulation with TNF or IL-1, highlighting the 
nonredundant role of HOIL-1 and HOIP in NF-B activa-
tion (Fig. 4 C). Overall, these data confirm that the mis-
sense L72P mutation of HOIP is responsible for both the 
destabilization of LUBAC and the impairment of NF-B 
activation in fibroblasts.
Figure 3. Impaired TNF- and IL--induced NF-B activation in the HOIP-deficient patient. (A) Time-course of IL-1–stimulated (left) or TNF-
stimulated (right) SV40-immortalized fibroblasts from control, HOIP-, and HOIL-1–deficient patients, with immunoblotting for phospho-IKK (p-IKK), IKK, 
IB, NEMO, and -tubulin. (B) IL-6 production upon stimulation with TNF and IL-1 in SV-40 fibroblasts from two controls, HOIP- (Patient), HOIL-1–, 
and NEMO-deficient patients (errors bars indicate the SEM; 3 independent experiments). Unpaired Student’s t tests were performed for the statistical 
analysis (**, P < 0.01; ***, P < 0.001). (C) Impaired recruitment of NEMO to punctate structures in the patient’s fibroblasts. TNF- or IL-1–stimulated cells 
were permeabilized with saponin before fixation, and immunolocalization with anti-NEMO antibody (white) was performed. Nuclei were stained with 
DAPI. Bar, 10 µm. (D) Absence of linear polyubiquitination in the patients’ fibroblasts upon TNF or IL-1 stimulation. Immunolocalization with anti-linear 
ubiquitin chains antibody (red) was performed as in C. Nuclei were stained with DAPI. Bars, 10 µm.
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perhaps accounting at least in part for the patient’s hypogam-
maglobulinemia and nonprotective antibody responses to 
S. pneumoniae and H. influenzae.
Enhanced response to IL- in HOIP-deficient monocytes
We then investigated the cellular basis for the inflammatory 
phenotype observed in the HOIP-deficient patient (see case 
report in Discussion). Upon stimulation in vitro with IL-1 
for 48 h, the patient’s PBMCs produced similar amounts of 
IL-6 and IL-10 than controls (Fig. 6 A). In contrast, the 
patient’s cells failed to produce IL-10 in response to TNF 
(Fig. 6 A). Monocytes from HOIL-1–deficient patients have 
been reported to be hyperresponsive to IL-1, probably ac-
counting for the clinical autoinflammation observed in these 
patients (Boisson et al., 2012). We thus investigated the re-
sponse of various leukocyte subsets from the HOIP-deficient 
patient, healthy controls, and IRAK4-deficient patients to 
in vitro stimulation with TNF, IL-1, LPS, or a combination of 
PMA, ionomycin, and CpG-B. The various PBMC subsets 
were identified on the basis of cell surface expression of the 
following markers: CD3 (T cells), CD19 (B cells), CD56 
(NK cells), and CD14 (monocytes). The production of IL-6, 
IL-8, MIP-1, MIP-1, IL-1, and IFN- was assessed by intra-
cellular staining and flow cytometry. Upon IL-1 stimula-
tion, the proportion of monocytes producing IL-6 and IL-1 
was higher in the patient than in healthy controls (13.1 ± 4% 
vs. 4.4 ± 1.0%, and 29.7 ± 8% vs. 13.8 ± 1.8%, respectively), 
whereas IRAK-4–deficient monocytes were unresponsive 
(Fig. 6 B). Moreover, the patient’s monocytes produced IL-8 
and MIP-1 in amounts similar to those for the control 
(Fig. 6 B). In conclusion, whole blood and PBMCs from the 
HOIP-deficient patient appear to respond strongly to IL-1, 
like HOIL-1–deficient cells, potentially accounting for the 
clinical autoinflammation observed in this patient.
DISCUSSION
We have identified the first case of autosomal recessive HOIP 
deficiency in a patient with systemic autoinflammation, com-
bined immunodeficiency, systemic lymphangiectasia, and mild 
amylopectinosis. Our study fulfills the criteria for genetic stud-
ies in single patients (Casanova et al., 2014). HOIP, HOIL-1, 
and SHARPIN are the three components of LUBAC, the 
E3-ligase complex responsible for linear ubiquitination (Iwai 
and Tokunaga, 2009; Gerlach et al., 2011; Ikeda et al., 2011; 
Tokunaga et al., 2011). We found that L72P mutation de-
stabilized HOIP and, consequently, SHARPIN and HOIL-1. 
This situation is reminiscent of humans with inherited HOIL-1 
deficiency (Boisson et al., 2012). In Hoil1 (Tokunaga et al., 
2009), Sharpin (Gerlach et al., 2011), and Hoip (Peltzer et al., 
2014) knockout mice, and in B cell-specific conditional Hoip 
knockout mice (Sasaki et al., 2013), the absence of one sub-
unit of LUBAC impairs the expression of the other two sub-
units, suggesting that LUBAC is a ternary complex in both 
mice and humans. LUBAC is involved in the NF-B path-
way, in which it conjugates linear polyubiquitin chains to 
specific Lys residues of NEMO (Tokunaga et al., 2009) and 
cells, when compared with abolished signalization in CD40-
deficient cells and normal signalization in control cells (Fig. 5 C). 
HOIP is thus essential for CD40 activation in human B cells, 
Figure 4. Complementation of impaired NF-B activation by  
reintroduction of the WT HOIP allele. (A) Immunoblot of the three  
LUBAC subunits in SV-40–immortalized fibroblasts from control, HOIP-
deficient (Patient), and HOIL-1–deficient cells expressing empty vector (-)  
or WT-V5 HOIP constructs (+). (B) Time course of IL-1stimulated (top)  
or TNF-stimulated (bottom) SV-40–immortalized fibroblasts from control, 
HOIP-deficient (Patient-empty), and HOIP-deficient cells complemented 
with WT HOIP (Patient-HOIP), with immunoblotting for p-IKK, IKK, IB, 
and GAPDH. (C) IL-6 production in SV-40 fibroblasts from control, HOIP- 
(Patient), or HOIL-1–deficient patients without (-) and with (+) WT HOIP 
complementation, after stimulation with TNF or IL-1. Errors bars represent 
the SEM (five independent experiments). Unpaired Student’s t tests were used 
for the statistical analysis (**, P < 0.01; ***, P < 0.001; ns, not significant).
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NF-B activation are impaired, as in HOIL-1–deficient pa-
tients. We also showed that linear ubiquitination is actually 
abolished in HOIP-deficient fibroblasts, which we had shown 
only recently for HOIL-1 deficiency (Boisson et al., 2012; 
RIP1 (Gerlach et al., 2011). This activity is essential for full 
NF-B activation in mice (Tokunaga et al., 2009; Ikeda et al., 
2011; Zak et al., 2011). We showed in human HOIP-deficient 
fibroblasts that LUBAC expression and TNF- and IL-1-driven 
Figure . Impaired B cell activation in 
the HOIP-deficient patient. (A) Flow cytom-
etry analysis of CD80 expression from stimu-
lated PBMCs. PBMCs left unstimulated or 
stimulated for 3 d as indicated were stained 
for CD19 and with either an isotype control 
(red histograms) or an antibody directed 
against CD80 (blue histograms). CD80 expres-
sion values (CD80 median, isotype median) 
are indicated under the histograms (one  
experiment). (B) Flow cytometry analysis of 
CD27/CD38 expression on gated CD19+ cells, 
upon stimulation of PBMCs for 7 d with 
CD40L+IL-21 or with medium alone. The 
gated populations in the figure correspond  
to CD38hi and CD27hi plasmablasts (one  
experiment). (C) Time course of CD40L- 
stimulated EBV-immortalized B cells from 
control, HOIP- (patient), and CD40-deficient 
(CD40/) patients, followed by immuno-
blotting for p-IKK, IKK, IB, and GAPDH 
(two independent experiments).
Figure . Hyperproduction of IL- upon IL- stimulation in HOIP-deficient monocytes. (A) Production of IL-6 and IL-10 by whole blood cells 
after 48 h of stimulation with TNF, IL-1, LPS, and PMA/ionomycin in 32 controls (left), 2 travel controls (middle), and the HOIP-deficient patient (right,  
in red, 1 experiment). (B) Cytokine production in CD14+ cell subsets, as determined by intracellular FACS staining of stimulated PBMCs. PBMCs from 12 
healthy controls (black), the HOIP-deficient patient (red), an HOIL-1–deficient patient (blue), and an IRAK-4–deficient patient (gray) were stimulated with TNF,  
IL-1, or LPS. The secretory pathways were concomitantly blocked with monensin and Brefeldin A. 12 h after stimulation, the cells were immunolabeled 
with antibodies against CD14 and then permeabilized to assess the production of IL-6, IL-1, IL-8, and MIP-1 by intracellular immunostaining. Labeled 
cells were analyzed by flow cytometry (3 independent experiments; **, P < 0.01).
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However, in the Jurkat T cell line, HOIP knockdown impairs 
NF-B activation upon TCR activation (Dubois et al., 2014). 
Moreover, human inborn defects of NF-B signaling can lead 
to T cell defects, as seen with IB gain-of-function (Courtois 
et al., 2003) or IKK loss-of-function mutations (Pannicke 
et al., 2013; Mousallem et al., 2014; Nielsen et al., 2014). Overt 
T cell deficiency is more rarely seen in patients with hypo-
morphic mutations in NEMO (Döffinger et al., 2001; Casanova 
et al., 2011). Overall, inborn errors of LUBAC, like inborn 
errors of NF-B, may underlie T cell deficiencies, a fea-
ture that apparently depends on the nature of the disease-
causing gene.
Systemic lymphangiectasia may have also contributed to 
T cell lymphopenia in this patient, by lymphatic leak (Fuss 
et al., 1998). Lymphangiectasia has not been observed in HOIL-1– 
deficient patients (Boisson et al., 2012; Nilsson et al., 2013; 
Wang et al., 2013) and in Hoil/ mice (Tokunaga et al., 
2009). Although lymphangiectasia has not been reported in 
Sharpin/ mice, they display dilation of the dermal, mouth, 
esophagus, and stomach capillaries (HogenEsch et al., 1993), 
similar to this patient’s intestinal capillaries (see Case report). 
Moreover, Hoip/ mice die in utero due to disrupted vascu-
lature caused by TNFR1-mediated endothelial cell death 
(Peltzer et al., 2014). Conditional endothelial cell IKK KO 
mice also exhibit increased vasculature permeability (Ashida 
et al., 2011). Improper TNFR1 signaling seems to activate 
aberrant responses, in particular the formation of cytoplasmic 
complex II, triggering cell death. Overall, the circulatory and 
lymph vessel phenotypes of Hoip-deficient mice and HOIP-
deficient patients suggest that HOIP, alone or less likely as a 
subunit of LUBAC, may regulate these systems. Finally, the 
HOIP-deficient patient displayed patches of cellular amylo-
pectinosis, with muscular weakness at the lower extremities, 
but normal electromyography, and without clinical or echo-
graphic signs of cardiomyopathy. This contrasts with HOIL-1– 
deficient patients, whose amylopectinosis was an early onset, 
severe, and consistent manifestation, even in patients whose 
mutations were not proven to be loss-of-function (Boisson 
et al., 2012; Nilsson et al., 2013; Wang et al., 2013). The milder 
amylopectinosis in the HOIP-deficient patient suggests that 
amylopectinosis may be more dependent on HOIL-1 than 
HOIP, LUBAC, and NF-B. Alternatively, the HOIP L72P 
mutation may not be completely loss-of-function.
Case report
The patient, a 19-yr-old woman of Kuwaiti origin, was born 
at term, after a twin pregnancy. Her parents are first cousins 
and her twin brother is healthy. During the neonatal period, 
she presented omphalitis, requiring antibiotic treatment, and 
splenomegaly. After discharge, she had recurrent episodes of 
fever and persistent splenomegaly, associated with mild liver 
enlargement. At the age of 2 yr, familial Mediterranean fever 
was suspected, leading to the treatment of the patient for 
3 yr with colchicine, with no clinical benefit. From early 
childhood, the growth of the patient was stunted. At the age 
of 4 yr, she developed generalized lymphadenopathy after 
Tarantino et al., 2014), connecting this biological activity 
with NF-B activation in humans. Overall, our results dem-
onstrate that human HOIP and HOIL-1 are both essential for 
LUBAC activity and for TNF-, IL-1–, and CD40L-induced 
NF-B responses, at least in fibroblasts and B cells.
This HOIP-deficient patient displayed autoinflammation, 
like three patients with HOIL-1 deficiency (Boisson et al., 
2012). The apparent lack of autoinflammation (and immuno-
deficiency) in most of the other patients carrying bi-allelic 
mutations in HOIL-1 (Nilsson et al., 2013; Wang et al., 2013) 
may result from insufficient clinical characterization from at 
least one mutant allele being hypomorphic, from the impact 
of genetic modifiers, or from differences in the exposure to 
microbial infections (MacDuff et al., 2015). At any rate, the 
unusual association of IL-1 hyporesponsiveness in fibroblasts 
and hyperresponsiveness in monocytes from HOIP- or HOIL-1– 
deficient patients may be responsible for autoinflammation. 
In particular, we confirmed that the absence of LUBAC 
(or its presence in only very small amounts) leads to the over-
expression of inflammatory genes and IL-1 hyperrespon-
siveness in mononuclear leukocytes, including monocytes in 
particular. Hoip/ mice die during embryonic development 
(Sasaki et al., 2013; Peltzer et al., 2014), unlike Hoil1/ and 
Sharpin/ mice (HogenEsch et al., 1993; Tokunaga et al., 
2009). The HOIP-deficient patient has several features in 
common with Hoil1/ (MacDuff et al., 2015) and Sharpin/ 
mice (HogenEsch et al., 1999, 2001; Seymour et al., 2007; 
Gerlach et al., 2011; Ikeda et al., 2011; Liang et al., 2011; 
Tokunaga et al., 2011), which display chronic severe eosin-
ophilic inflammation. The production of proinflammatory 
cytokines upon IL-1 stimulation was not investigated in 
monocytes from Sharpin knockout mice, but the inflamma-
tory phenotype of these mice was partially rescued by Il1rap 
(Liang et al., 2011) or Tnf (Gerlach et al., 2011) inactivation, 
or treatment with the proteasome inhibitor bortezomib, which 
inhibits NF-B activation (Liang et al., 2011). The autoinflam-
mation associated with LUBAC deficiency may be caused by 
NF-B over-activation in response to certain stimuli in some 
cell types. These data provide interesting possibilities for 
therapeutic intervention.
Both HOIL-1– and HOIP-deficient patients had neo-
natal bacterial infections and impaired antibody response to 
S. pneumoniae and H. influenzae (Boisson et al., 2012). The 
HOIP-deficient patient also presented a broad impairment of 
antibody production not seen in HOIL-1–deficient patients, 
a slight excess of naive and transitional B cells and distinctive 
defects of CD40-dependent B cell activation and plasmablast 
differentiation. Interestingly, B cell-specific Hoip knockout 
mice have low levels of peritoneal B1 cells and markedly de-
creased serum levels of all immunoglobulin isotypes, proba-
bly due to a defect of the CD40 pathway (Sasaki et al., 2013). 
Moreover, the HOIP-deficient patient had severe T cell lym-
phopenia, affecting the naive compartment in particular, ac-
companied by an increase in the proportions of effector 
memory CD4+ and TEMRA CD8+ cells. These abnormalities 
have not been observed in patients with HOIL-1 deficiency. 
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of the pelvis demonstrated diffuse muscular atrophy, with 
fatty infiltration of the gluteal musculature and the abduc-
tors. However, motor and sensory conduction and needle 
electromyography were normal, and there was no evidence 
of cardiomyopathy at heart ultrasound. Creatine phosphoki-
nase (CK) and LDH levels are within the normal limits. Pul-
monary function tests have shown reduced forced expiratory 
volume (78% of predicted), but to a lower extent than has been 
reported in HOIL-1 deficient patients. The patient is still on 
antibiotic prophylaxis, a low-fat and high-protein diet, iron and 
vitamin D supplementation, and immunoglobulin replacement 
therapy, and has started treatment with octreotide.
MATERIALS AND METHODS
Sample collection. This study was conducted in accordance with the 
Helsinki Declaration, with informed consent obtained from the patient and 
her family. The study was approved by the local ethics committee of Necker-
Enfants Malades Hospital (Paris, France); Boston Children Hospital (Boston, 
MA); and The Rockefeller University Hospital (New York, NY).
Genetic analysis. For WES massively parallel sequencing, genomic DNA 
extracted from the patient’s peripheral blood cells was sheared with a Covaris 
S2 Ultrasonicator. An adapter-ligated library was prepared with the Paired-
End Sample Prep kit V1 (Illumina). Exome capture was performed with the 
SureSelect Human All Exon kit (Agilent Technologies). Paired-end se-
quencing was performed on a HiSeq 2500, generating 100-base reads. For 
sequence alignment, variant calling and annotation, we used BWA aligner 
(Li and Durbin, 2009) to align sequences with the human genome refer-
ence sequence (hg19 build). Downstream processing was performed with 
the Genome analysis toolkit (GATK; McKenna et al., 2010), SAMtools 
(Li et al., 2009), and Picard Tools. Substitution and indel calls were identi-
fied with a GATK Unified Genotyper and a GATK Indel GenotyperV2, re-
spectively. All calls with a read coverage ≤2x and a Phred-scaled SNP quality 
of ≤20 were filtered out. All the variants were annotated with the GATK 
Genomic Annotator.
For genotyping and linkage analysis, the patient, her parents, and her 
unaffected brother were genotyped with the Affymetrix GeneChip Human 
Mapping 250K array. Genotype calling was achieved with Power Tools 
(Affymetrix). We discarded monomorphic single-nucleotide polymorphisms 
(SNPs), SNPs with a call rate <100%, and SNPs presenting more than one 
Mendelian inconsistency within the family. SNPs were further filtered based 
on population-based filters, using HapMap CEU trios. Multipoint linkage 
analysis, assuming autosomal recessive inheritance with complete penetrance 
(homozygosity mapping), was performed using Merlin software (Abecasis 
et al., 2002) on 84,954 high-quality SNPs. Marker–marker linkage disequi-
librium was modeled by creating clusters including SNPs for which pairwise 
r2 was greater than 0.4 and all intervening SNPs (Abecasis and Wigginton, 
2005).The HapMap CEU trios were used to estimate pairwise r2 and haplo-
type frequencies of the clusters. We used different genomic database: Exome 
Aggregation Consortium (ExAC), 1000 Genome Project, and dbSNP all ac-
cessed in February 2015. CADD score for variation was calculated using the 
University of Washington’s CADD website.
Cell lines, immortalization, and complementation. Control and 
patient-derived fibroblasts were immortalized by transfection with a plasmid 
encoding the SV40 large-T antigen. Transformed cell lines were grown in 
DMEM (Invitrogen) supplemented with 10% fetal calf serum (Invitrogen). 
The human NEMO/ fibroblasts were provided by A. Smahi (Imagine In-
stitute, Paris, France; Smahi et al., 2000). The HOIP-V5 open-reading frame 
was amplified from a plasmid provided by Henning Walczak and inserted 
into the retroviral vector pMSCV (Life Science). Infectious viral particles 
were produced by cotransfecting GP2-293 packaging cells with pVSV-G 
and pMSCV-HOIP or an empty vector (Life Science). Viral particles were 
immunization with BCG. 1 yr later, she presented severe 
respiratory distress, requiring mechanical ventilation. Treat-
ment with rifampicin was initiated for possible mycobacterial 
disease. At the age of 7 yr, the patient began to suffer from 
recurrent episodes of fatty diarrhea, associated with fever and 
oral ulcers. Immunological investigations were performed for 
the first time at the age of 9 yr and showed T cell lympho-
penia (CD3+: 776 cells/µl), an impaired proliferative response 
to anti-CD3 (cpm: 1,106 vs. 35,216 in a normal control), 
and hypogammaglobulinemia (IgG: 315 mg/dl), associated 
with nonprotective antibody responses to S. pneumoniae  
and H. influenzae, but with a good antibody response to 
tetanus toxoid. Prophylaxis with cotrimoxazole was ini-
tiated. Additional abnormalities identified in laboratory 
tests included hypoalbuminemia (2.6 g/dl), hypocalcemia 
(8.2 mg/dl), anemia (Hb, 8.1 g/dl), iron deficiency (3.7 µmol/l), 
vitamin 25-OH D3 deficiency (7 nmol/l; n.v., 75–125 nmol/l), 
and an elevated ESR (97 mm/h) and high C-reactive protein 
(CRP) serum level (8.06 mg/dl). Endoscopies of the upper 
and lower gastrointestinal tract were unremarkable. The poor 
growth of the patient led to treatment with human recom-
binant growth hormone (hrGR). However, this treatment 
was complicated by femur fractures, leading to its cessation. 
At 15 yr of age, the patient complained of severe pain in 
the hips, knees, and ankles. Treatment with a nonsteroidal 
antiinflammatory drug (naproxen) led to clinical improve-
ment, but was complicated by gastrointestinal bleeding. Re-
current episodes of diarrhea and edema, requiring frequent 
infusions of albumin and furosemide, led to additional in-
vestigations. Negative results were repeatedly obtained for 
endoscopy, but videocapsule endoscopy, at the age of 16 yr, 
showed patchy areas of white-tipped thickened villi through-
out most of the small bowel, consistent with intestinal lym-
phangiectasia. Further evidence of lymph vessel abnormalities 
was provided by a lymphangiogram (showing abnormal fill-
ing of the thoracic duct), high -1-antitrypsin antibody, and 
triglyceride concentrations. The patient was placed on a low-
fat, high-protein diet, with some improvement, but she con-
tinued to suffer from fatty diarrhea, with poor weight gain 
and impaired linear growth. She also developed persistent 
warts. A chest CT scan at the age of 17 yr demonstrated mild 
bronchiectasis in the right middle and lower lobes. Labora-
tory examinations at 18 yr of age confirmed the T and B cell 
abnormalities (Table S2), associated with elevated fluctuating 
but consistently high ESR (between 26 and 119 mm/h), in-
creased CRP concentration (between 1.22 and 12.68 mg/dl; 
normal values: ≤0.5 mg/dl), and haptoglobin concentration 
(275 mg/dl; normal range: 33–183 mg/dl). Treatment with 
intravenous immunoglobulins was initiated, leading to an 
improvement in IgG trough levels. However, the episodes of 
systemic edema persisted, although at a lower frequency. The 
most recent follow-up visit showed a worsening of intesti-
nal lymphangiectasia. An endoscopy with biopsies showed 
dilated lymphatic space in duodenal, small intestinal, and co-
lonic mucosa. Moreover, the patient was suffering from mus-
cular weakness, especially in the lower extremities. An MRI 
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was quantified by RT-qPCR in a TaqMan Gene Expression Assay 
(Hs00215938_m1, Hs01047328_g1; Life Technologies), with normalization 
against GUS probes.
Cell stimulation, ELISA, and FACS analysis. For whole blood acti-
vation, fresh blood was first mixed with an equal volume of RPMI-1640 
(Invitrogen), left untreated, or treated with agonists for 48 h. Levels of 
IL-6 and IL-10 secretion were determined with ELISA kits (M9316 and 
M1910; Sanquin).
For B cell activation, PBMCs were purified by Ficoll gradient centrif-
ugation, and 106 cells were cultured in 24-well plates within 1 ml RPMI 
medium per well supplemented with 10% FBS and 50 U/ml penicillin 
(Invitrogen) and 50 µg/ml streptomycin (Invitrogen). The cells were stimu-
lated for 3 d with CD40L+IL-21, CD40L+IL-4, anti-IgM+CpG, or anti-
IgM+Cpg+BAFF (5 µg/ml CD40L, 200 ng/ml IL-21-Fc, BAFF, anti-IgM 
[1 µg/ml; Southern Biotech], CpG [500 nM; Invivogen], and IL-4 [1 ng/ml; 
R&D Systems]). PBMCs were harvested, blocked by incubation for 10 min 
in PBS+10% human serum, and stained by incubation for 30 min on ice, for 
CD19 (BioLegend), an isotype control or CD80 (eBioscience). Flow cytom-
etry analyses were performed on a BD LSRFortessa flow cytometer (BD). 
Cells were gated on CD19+ and CD80 expression was then analyzed with 
FlowJo software (Tree Star).
For plasmablast assay, PBMCs were cultured in RPMI supplemented 
with 10% FBS, 0.025% Hepes, 0.01% PenStrep, 0.01% sodium pyruvate, 
0.005% NEAA, 0.005% l-glutamine, and 0.0013% -mercaptoethanol) 
alone (unstimulated cells) or with 200 ng/ml IL-21-Fc and 5 µg/ml CD40 
ligand for a total of 7 d. Cells were stained with CD19-PECy5 (BioLegend; 
clone HIB19), CD27-APC (eBioscience; clone O323), or CD38-PECy7 
(BioLegend; clone HIT2) antibodies, and analyzed by flow cytometry on an 
LSR II machine (BD) with FlowJo software (Tree Star).
For leukocyte activation, frozen PBMCs were washed twice with FCS-
containing medium and used to seed 48-well plates (106 cells/well). They 
were cultured for 4–6 h, and then stimulated with TNF (20 ng/ml; R&D 
Systems) IL-1 (10 ng/ml; R&D Systems), LPS (10 ng/ml; Sigma-Aldrich), 
or PMA+ionomycin+CpGB (Sigma-Aldrich; 109 M + 107 M + 100 µg/ml). 
During stimulation, protein transport was blocked with GolgiStop and 
GolgiPlug (BD). Cells were stained with anti-CD3 (BD; #560366), anti-
CD19 (BD; #340951), anti-CD14 (BD; #557742), and anti-CD56 (Bio-
Legend; #318331) antibodies for cellular phenotyping and with Aqua Live/ 
Dead (Invitrogen) to exclude dead cells. After fixation and permeabilization 
(BD; #554722), the cells were stained with antibodies against IL-6 (BD; 
#561441), MIP-1 (BD; #554730), MIP-1 (BD; #560565), IL-1 (BD; 
#340515), IL-8 (BD; #511410), and IFN- (BD; #559326). Stained PBMCs 
were captured by flow cytometry with a LSRII flow cytometer (BD) and 
FACSDiva software (BD). The data were analyzed with FlowJo software 
(Tree Star).
Statistics. GraphPad Prism software was used to conduct unpaired, two-tailed 
Student’s t tests for sample analysis or one-way ANOVA followed by Tukey’s 
multiple comparison test. Values of P < 0.05 were considered significant.
Online supplemental material. Table S1, available as an Excel file, shows the 
immunological profile of the patient. Table S2, available as an Excel file, shows 
whole-exome sequencing data for the patient. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20141130/DC1.
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collected 48–72 h after transfection and used to infect SV40-transformed 
fibroblasts. Infected cells were selected with 0.4 µg/ml puromycin (Invitrogen). 
B lymphocyte cell lines from the patient and a healthy donor have been im-
mortalized with Epstein-Barr virus and grown in RPMI 1640 (Gibco) sup-
plemented with 15% fetal calf serum (Invitrogen).
Antibodies and reagents. The antibodies used for detection on immuno-
blots were anti-HOIL-1 N-ter, provided by H. Walczak (University College 
London, London, England, UK; Haas et al., 2009), anti-HOIL-1 C-ter pro-
vided by K. Iwai (Graduate School of Medicine, Kyoto University, Kyoto, 
Japan; Kirisako et al., 2006), anti-HOIP (PAB6229; Abnova), and anti-linear 
polyubiquitin chains 1F113F5/Y102L provided by Genentech (Matsumoto 
et al., 2012), anti-NEMO (sc-8330; Santa Cruz Biotechnology, Inc.; #611306; 
BD), anti-SHARPIN (14626–1-AP; ProteinTech), anti-IB (#610690; BD), 
anti-phospho-IKK- (ser176/180; 16A6; Cell Signaling Technology), anti-
IKK (AM8109a, Abgent), anti--tubulin (T4026; Sigma-Aldrich), and 
anti-GAPDH (sc-365062; Santa Cruz Biotechnology, Inc.) antibodies. 
Species-specific secondary antibodies coupled to horseradish peroxidase 
were obtained from Vector Laboratories or Amersham-Pharmacia.
Immunostaining. Periodic acid-Shift (PAS) staining was done using a stan-
dard clinical histopathology laboratory procedure. Sections of frozen tissue 
or formalin fixed from a sternocleidomastoid muscle biopsy were deparaf-
finized and rehydrated, then either rinsed in water or incubated with 1% dia-
stase (Sigma-Aldrich) in distilled water for 60 min at 60°C, followed by 
rinsing in water for 2 min. Slides were then incubated with 0.5% periodic 
acid (Poly-Scientific R&D) for 5 min, rinsed four times in distilled water, 
placed in Schiff’s solution (Poly-Scientific R&D) for 15 min, rinsed in tap 
water for 10 min, counterstained with Harris hematoxylin (Poly-Scientific 
R&D) for 5 min, and rinsed in water again for 5 min. After quick dipping in 
0.5% acid alcohol, slides were extensively rinsed in water before dehydra-
tion, clearing, and mounting in permanent mounting media. The presence 
of amylopectinosis was documented by persistence of PAS-positive material 
in diastase-treated sections. Images have been captured with an BX43 micro-
scope and DP25 digital camera (both from Olympus).
Cell lysis, immunoprecipitation, and immunoblotting. Cells were 
lysed in a buffer containing 30 mM Tris-HCl, pH 7.5, 120 mM NaCl, 2 mM 
KCl, 1% Triton X-100, and 2 mM EDTA supplemented with protease and 
phosphatase inhibitors (Complete and PhoStop; Roche). For immunopre-
cipitation, antibodies (5 µg) were added to 1 mg of total protein extract and 
incubated overnight at 4°C. Protein A– or protein G–coupled agarose beads 
(Sigma-Aldrich) were added to the samples, which were then incubated for 
1 h at 4°C. Beads were washed three times in lysis buffer and resuspended in 
Laemmli buffer.
Immunofluorescence. For immunofluorescence, cells cultured on glass 
coverslips were treated twice with ice-cold saponin extraction buffer (80 mM 
Pipes, pH 6.8, 1 mM MgCl2, 1 mM EGTA, and 0.1% saponin) for 2 min 
and 4 min on ice as previously described (Tarantino et al., 2014). Cells were 
then washed twice with PBS before fixation in 100% methanol. The cells 
were progressively rehydrated by successive washes with 85, 70, and 50% 
ethanol in water and two final washes with PBS. After blocking by incubation 
with 1% BSA in PBS, the slides were incubated with rabbit anti-NEMO 
antibodies or with human anti-linear polyubiquitin, washed with PBS and 
incubated either with anti–rabbit Alexa Fluor 488 or anti–human Alexa 
Fluor 546 secondary antibodies (Life Technologies). The slides were then 
washed again and incubated with DAPI (Sigma-Aldrich) to stain the nuclei. 
The coverslips were mounted in Mowiol supplemented with an anti-fading 
agent (AF100; Biovalley). Specimens were examined with an ApoTome 
imaging system (Imager Z1; Carl Zeiss) equipped with a 63×/1.4 oil DIC 
objective (Carl Zeiss).
Gene expression and qPCR analysis. RNA was extracted from SV40-
transformed fibroblasts with TRIzol (Invitrogen) and reverse-transcribed (2 µg) 
with the SuperScript III first-strand synthesis kit (Invitrogen). HOIP expression 
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